In the offering, the company will look to float approximately 1.5 million shares and 1.5 million Series A warrants at $7.40 per share.
InVIvo Therapeutics has not yet announced the exercise price of the warrants, which will be exercisable upon issuance and will expire 20 years from the date they were issued, according to the SEC filing.
The company will also offer pre-funded warrants to purchase excess shares in lieu of common shares for purchasers who would own more than 4.99% of the company after purchasing the combined shares and warrants.
The offering also comes with a 45-day underwriter’s option to purchase an additional 222,973 shares, which could bring in an extra $1.7 million for InVivo, according to the SEC filing.
In May, InVivo Therapeutics saw shares rise as much as 75% after it released complete six-month results from the company’s Inspire study of its neuro-spinal scaffold, which it ended in January after halting enrollment last July.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.